Comparison of seroconversion rates with CAM-70 measles vaccine at different dosages

• Autor(a) principal: Camacho, Luiz Antonio B
• Data de Publicação: 2000
• Outros Autores: Freire, Marcos Silva, Yamamura, Anna MY, Leal, Maria da Luz, Mann, George
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista de Saúde Pública
• Texto Completo: https://www.revistas.usp.br/rsp/article/view/25034
• topic: Vacina contra sarampo^i1^sadministração e dosa; Ensaios controlados aleatórios; Sarampo^i1^sprevenção e contr; Testes sorológicos; Anticorpos antivírus^i1^sanál; Vacinas virais; Measles vaccine^i2^sadministration and dos; Randomized controlled trials; Measles^i2^sprevention and cont; Serologic tests; Antibodies; viral^i2^sanaly; Viral vaccines

OBJECTIVES: To compare seroconversion rates induced by Biken CAM-70 measles vaccines at different viral concentrations. METHODS: Healthy children aged 9 to 18 months from a primary health care unit in Rio de Janeiro, Brazil, and whose guardians agreed with their participation, were randomly assigned to receive one of the following vaccine formulations: 5,000, 1,000 or 200 CCID50 (50% Tissue Culture Infective Dose). The research team, participants, and data analysts were blinded to the type of vaccine administered. Pre- and post-vaccination antibody levels were assessed through Plaque Reduction Neutralization Test. Two interim data analyses were planned to assess unequivocal evidence of the superiority of one of the vaccine types. RESULTS: From 223 recruited children, 84% completed the whole course. Of them, 79% were less than 10 months of age, and 93% did not show detectable measles antibodies in pre-vaccination serum. Seroconversion (four-fold increase in antibody levels) in groups vaccinated with 5,000, 1,000 or 200 CCID50, were 82%, 55%, and 37% (p